selected scholarly activity
-
chapters
- Effusions. 925-944. 2008
-
conferences
- Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study. Journal of Thoracic Oncology. S248-S248. 2024
- EBUS/EUS and Lung Cancer Resection Staging Concordance in 669 Patients. Laboratory Investigation. S1905-S1905. 2024
- A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A). Journal of Clinical Oncology. 2023
- Dose-escalation Study of [225Ac]-FPI-1434 (FPI-1434) in Patients (pts) with IGF-1R Expressing Advanced Solid Tumors: Preliminary Pharmacology and Dosimetry Results. Journal of Nuclear Medicine. 2023
- Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).. Journal of Clinical Oncology. 2023
- EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S261-S262. 2022
- EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L. Journal of Thoracic Oncology. S412-S413. 2022
- OCELOT - Osimertinib then Chemotherapy in EGFR plus Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L. Journal of Thoracic Oncology. S412-S413. 2022
- Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status. Virchows Archiv. S26-S26. 2022
- The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S261-S262. 2022
- Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research. CT561-CT561. 2022
- KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research. 2022
- 2021 Canadian Surgery Forum. Canadian Journal of Surgery. S80-S159. 2021
- 459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC. Journal for ImmunoTherapy of Cancer. A488-A488. 2021
- Does Tumor Response Correlate With Quality of Life Changes Following LU177 DOTATATE Therapy for Neuroendocrine Tumors? Observations From a Multicenter Prospective Study (NCT02743741). International Journal of Radiation Oncology Biology Physics. e81-e82. 2021
- Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease. International Journal of Radiation Oncology Biology Physics. e479-e479. 2021
- 52: Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease. Radiotherapy and Oncology. S25-S25. 2021
- Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology. S1089-S1090. 2021
- OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S876-S876. 2021
- P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC. Journal of Thoracic Oncology. S1010-S1011. 2021
- P45.10 Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology. S1089-S1090. 2021
- Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC. Journal of Thoracic Oncology. S1010-S1011. 2021
- Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and curative esophagectomy: A systematic review and meta-analysis.. Journal of Clinical Oncology. e16083-e16083. 2021
- The PROVIEW+ tool: Developing and validating a tool to predict risk of poor performance status and severe symptoms in cancer patients over time.. Journal of Clinical Oncology. 12095-12095. 2021
- Clinical Activity of BMS-986012, an AntieFucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer. Journal of Thoracic Oncology. S195-S195. 2021
- Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. S689-S689. 2021
- FP03.03 Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer. Journal of Thoracic Oncology. S195-S195. 2021
- P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. S689-S689. 2021
- Optimizing the SPECT Imaging Workflow For Individualized Dosimetry in Lu177-DOTATATE Treatment Of Progressive Metastatic Neoendocrine Tumors. International Journal of Radiation Oncology Biology Physics. e588-e589. 2020
- 1195P The value of detecting resistance through liquid biopsy. Annals of Oncology. S786-S787. 2020
- 152: Toxicity Assessment of Individualized Dosimetry Adjusted PRRT - Interim Report of the Ontario Consortium Trial OZM 067. Radiotherapy and Oncology. S65-S66. 2020
- TOXICITY ASSESSMENT OF INDIVIDUALIZED DOSIMETRY ADJUSTED PRRT - INTERIM REPORT OF THE ONTARIO CONSORTIUM TRIAL OZM 067. Radiotherapy and Oncology. S65-S66. 2020
- Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress. Clinical Cancer Research. A26-A26. 2020
- Defining VALUE: Routine liquid biopsy in NSCLC diagnosis-a Canadian trial in progress. Clinical Cancer Research. 47-48. 2020
- Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. Journal of Clinical Oncology. 3546-3546. 2020
- Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. Journal of Clinical Oncology. 2020
- Development and validation of a risk prediction model for poor performance status and severe symptoms among cancer patients.. Journal of Clinical Oncology. 12097-12097. 2020
- Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.. Journal of Clinical Oncology. e21714-e21714. 2020
- Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.. Journal of Clinical Oncology. 2020
- Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. Journal of Clinical Oncology. 2020
- Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.. Journal of Clinical Oncology. 54-54. 2020
- 70 Quantifying Tumour Dose Using Individualized Dosimetry Methodology in 177LU Dotatate Therapy. Radiotherapy and Oncology. S32-S32. 2019
- MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226. Journal of Thoracic Oncology. S291-S292. 2019
- P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S379-S380. 2019
- Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy. Annals of Oncology. v179-v179. 2019
- Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND226 study of durvalumab +/- tremelimumab in combination with platinum-doublet chemotherapy. Annals of Oncology. 2019
- QUANTIFYING TUMOUR DOSE USING INDIVIDUALIZED DOSIMETRY METHODOLOGY IN 177LU DOTATATE THERAPY. Radiotherapy and Oncology. S32-S32. 2019
- Communication with pathology evaluated via the pathology requisition using 396,033 pathology reports. Virchows Archiv. S133-S134. 2019
- Quantifying Renal And Tumor Doses with Individualized Dosimetry In 177Lu DOTATATE Therapy – What Difference Does It Make?. International Journal of Radiation Oncology Biology Physics. S205-S205. 2019
- Visceral pleural invasion by tumour size, cancer type and pathologist in 1,560 resections. Virchows Archiv. S42-S43. 2019
- A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.. Journal of Clinical Oncology. 2599-2599. 2019
- A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.. Journal of Clinical Oncology. TPS3152-TPS3152. 2019
- Individualized dosimetry for Lu177 DOTATATE therapy - What difference does it make?. Journal of Nuclear Medicine. 2019
- Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice. Annals of Oncology. ii65-ii65. 2019
- MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE). Journal of Thoracic Oncology. S362-S362. 2018
- P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. Journal of Thoracic Oncology. S458-S458. 2018
- P1.09-04 Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region. Journal of Thoracic Oncology. S551-S551. 2018
- P2.09-08 Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S764-S764. 2018
- P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis. Journal of Thoracic Oncology. S803-S803. 2018
- The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review. Annals of Oncology. viii690-viii690. 2018
- 200PD High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center. Journal of Thoracic Oncology. S120-S120. 2018
- MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226. Journal of Thoracic Oncology. S1839-S1839. 2017
- OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update. Journal of Thoracic Oncology. S1792-S1793. 2017
- P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients. Journal of Thoracic Oncology. S2426-S2427. 2017
- Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Annals of Oncology. 2017
- Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Annals of Oncology. v539-v539. 2017
- Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.. Journal of Clinical Oncology. 3058-3058. 2017
- Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.. Journal of Clinical Oncology. 9093-9093. 2017
- MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. Journal of Thoracic Oncology. S392-S393. 2017
- OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012. Journal of Thoracic Oncology. S250-S251. 2017
- A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226). European Journal of Cancer. S95-S95. 2016
- CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. Journal of Thoracic Oncology. S250-S251. 2016
- ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. Journal of Thoracic Oncology. S250-S251. 2016
- NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Annals of Oncology. vi577-vi577. 2016
- Comparison of Three Commercially Available Platforms for Somatic Mutation Profiling in Solid Tumors. Cancer genetics. 287-287. 2016
- CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.. Journal of Clinical Oncology. 3001-3001. 2016
- 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. European Journal of Cancer. S632-S632. 2015
- 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). European Journal of Cancer. S632-S633. 2015
- Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. S176-S176. 2015
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. Journal of Clinical Oncology. 2015
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. Journal of Clinical Oncology. 8046-8046. 2015
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.. Journal of Clinical Oncology. 8025-8025. 2015
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.. Journal of Clinical Oncology. 2015
- NIVOLUMAB AND IPILIMUMAB IN FIRST-LINE NON-SMALL-CELL LUNG CARCINOMA (NSCLC): INTERIM PHASE I RESULTS. Asia-Pacific Journal of Clinical Oncology. 155-155. 2014
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. International Journal of Radiation Oncology Biology Physics. S31-S31. 2014
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. S2-S2. 2014
- Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. S32-S33. 2014
- NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Journal of Thoracic Oncology. S153-S153. 2014
- Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology. iv363-iv363. 2014
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.. Journal of Clinical Oncology. 8024-8024. 2014
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.. Journal of Clinical Oncology. 2014
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.. Journal of Clinical Oncology. 8023-8023. 2014
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 8113-8113. 2014
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology. 2013
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology. 8072-8072. 2013
- Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations.. Journal of Clinical Oncology. e18147-e18147. 2012
- Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations.. Journal of Clinical Oncology. 2012
- Abstract ED03-04: Using epigenetic biomarkers as prognostic and predictive markers in non-small cell lung cancer (NSCLC) and the promise of epigenetic therapy. Cancer Epidemiology, Biomarkers and Prevention. ed03-04-ed03-04. 2011
- BIOMARKER DEVELOPMENT FOR A PHASE II STUDY OF COMBINATION EPIGENETIC THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Journal of Thoracic Oncology. S1101-S1101. 2011
- A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.. Journal of Clinical Oncology. e14644-e14644. 2011
- Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.. Journal of Clinical Oncology. 3098-3098. 2011
- Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer. Cancer Research. 2011
- Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.. Journal of Clinical Oncology. 3016-3016. 2010
- Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC).. Journal of Clinical Oncology. e14532-e14532. 2010
- A phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC): an interim analysis. Journal of Thoracic Oncology. S306-S307. 2009
- Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). Journal of Clinical Oncology. 8055-8055. 2009
- Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). Journal of Clinical Oncology. 2009
- Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC). Journal of Clinical Oncology. 19036-19036. 2008
- Gemcitabine (G) and vinorelbine (V) in patients (pts) with recurrent advanced non-small cell lung cancer (NSCLC): Sequence of administration matters. Journal of Clinical Oncology. 17101-17101. 2006
-
journal articles
- A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.. Clinical Lung Cancer. 26:146-151. 2025
- Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.. Immunotherapy. 17:257-268. 2025
- A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.. Clinical Lung Cancer. 26:e22-e32.e2. 2025
- The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.. Therapeutic Advances in Medical Oncology. 17:17588359241308784. 2025
- Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study.. Therapeutic Advances in Medical Oncology. 17:17588359251332154. 2025
- Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process.. Current Oncology. 31:6512-6535. 2024
- Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective.. Current Oncology. 31:6017-6031. 2024
- Can Individualized Dosimetry Improve Treatment Efficacy for 177Lu-DOTATATE (D) Therapy in Primary Site Agnostic Neuroendocrine Tumors?. International Journal of Radiation Oncology Biology Physics. 120:E288-E288. 2024
- P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study. Journal of Thoracic Oncology. 19:s248. 2024
- Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer. International Journal of Cancer. 155:963-978. 2024
- Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study. Lung Cancer. 194:107898-107898. 2024
- A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.. Journal of Clinical Oncology. 42:TPS8669-TPS8669. 2024
- Quality of life (QoL) benefits following 177Lu-DOTATATE therapy in patients (pts) with 68Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET).. Journal of Clinical Oncology. 42:e16291-e16291. 2024
- What is a bad ALK? A scoping review of molecular markers of poor prognosis.. Journal of Clinical Oncology. 42:e20530-e20530. 2024
- Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement. Current Oncology. 31:1803-1816. 2024
- 44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. ESMO Open. 9:102273-102273. 2024
- A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.. Journal of Clinical Oncology. 42:TPS232-TPS232. 2024
- Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.. PLoS ONE. 19:e0314205. 2024
- SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Annals of Oncology. 35:66-76. 2024
- Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response. Current Oncology. 31:1-23. 2023
- Current and Future Treatment Options in the Management of Stage III NSCLC. Journal of Thoracic Oncology. 18:1478-1491. 2023
- Rates of surgery and adjuvant chemotherapy use in patients with stage IB to IIIA non-small cell lung cancer: A provincial population-based study.. JCO Oncology Practice. 19:134-134. 2023
- 1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis). Annals of Oncology. 34:S766-S766. 2023
- 663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. Annals of Oncology. 34:S466-S467. 2023
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. 29:2559-2569. 2023
- Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire. Current Oncology. 30:7627-7637. 2023
- Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology. 30:6559-6574. 2023
- Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Current Oncology. 30:6473-6496. 2023
- Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer. Current Oncology. 30:6289-6315. 2023
- A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).. Journal of Clinical Oncology. 41:TPS2673-TPS2673. 2023
- Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).. Journal of Clinical Oncology. 41:TPS9160-TPS9160. 2023
- Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. Current Oncology. 30:4527-4537. 2023
- Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses. Cancer Research. 83:CT202-CT202. 2023
- Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36. Cancer Research. 83:CT212-CT212. 2023
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. Oncology. 37:176-183. 2023
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma. Oncology. 37:175-184. 2023
- Prevalence of Thyroid Transcription Factor-1 (TTF-1)-Negative Small Cell Carcinoma and Napsin A Positivity in Small Cell Carcinoma in a Cross-Sectional Study of Lung Core Biopsies. Cureus. 15:e37015. 2023
- Assessing Access to And Outcomes of Medical Oncology and Radiation Oncology Consultation in Non-Small Cell Lung Cancer Patients: A Population-Based Study Using Administrative Data. Medical Research Archives. 11. 2023
- Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history. PLoS ONE. 18:e0294154-e0294154. 2023
- Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. Cancer Treatment and Research Communications. 37:100774-100774. 2023
- Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. Journal of Medical Economics. 25:993-1004. 2022
- BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. JTO Clinical and Research Reports. 3:100400-100400. 2022
- Physician and Surgeon Communication Assessed via the Pathology Requisition in a Regional Laboratory Over Ten Years. Cureus. 14:e27714. 2022
- Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 42:666-672. 2022
- Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. Acta Oncologica. 61:705-713. 2022
- Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.. Acta Oncologica. 61:705-713. 2022
- Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy. Annals of Surgery. 275:91-98. 2022
- The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14:175883592211126-175883592211126. 2022
- Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology. 28:4552-4576. 2021
- The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. Current Oncology. 28:4392-4407. 2021
- Development and validation of a prediction model of poor performance status and severe symptoms over time in cancer patients (PROVIEW+). Palliative Medicine. 35:1713-1723. 2021
- Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE. Journal of Nuclear Medicine. 62:1406-1414. 2021
- The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 160:136-151. 2021
- Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada. Lung Cancer. 157:40-47. 2021
- Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports. PLoS ONE. 16:e0253876-e0253876. 2021
- The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13:175883592110563-175883592110563. 2021
- Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review. Journal of Patient-Reported Outcomes. 4:58. 2020
- Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. Oncologist. 25:981-992. 2020
- A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs. 38:1442-1447. 2020
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. The Lancet Oncology. 21:1066-1076. 2020
- A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer. 143:1-11. 2020
- Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology. 27:146-155. 2020
- Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer. JAMA network open. 3:e201768-e201768. 2020
- Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. Current Oncology. 27:78-86. 2020
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 579:284-290. 2020
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 382:41-50. 2020
- Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist. 25:64-77. 2020
- Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 134:259-267. 2019
- Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario. Current Oncology. 26:247-252. 2019
- Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Investigational New Drugs. 37:498-506. 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 393:1819-1830. 2019
- Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology. 26:81-93. 2019
- Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology. 25:384-392. 2018
- Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Current Oncology. 25:317-328. 2018
- Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. Journal of Thoracic Oncology. 13:1363-1372. 2018
- Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. Cancer Treatment Reviews. 65:65-77. 2018
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet Oncology. 19:521-536. 2018
- Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology. 25:73-82. 2018
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 378:113-125. 2018
- A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC. EJNMMI Research. 7:8. 2017
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. 18:436-440.e1. 2017
- Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitators. Supportive Care in Cancer. 25:2297-2304. 2017
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. New England Journal of Medicine. 376:2415-2426. 2017
- Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. Current Oncology. 24:111-119. 2017
- Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. Cancer Treatment Reviews. 54:43-57. 2017
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet Oncology. 18:31-41. 2017
- Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. 18:34-42.e2. 2017
- Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology. 7:67. 2017
- Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey. Clinical Oncology. 28:667-667. 2016
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 34:2980-2987. 2016
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 34:2969-2979. 2016
- Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22:2897-2907. 2016
- Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Current Oncology. 23:196-200. 2016
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. Journal of Clinical Oncology. 34:1676-1688. 2016
- Imaging Biomarkers in Immunotherapy. Biomarkers in Cancer. 8s2:BIC.S31805-BIC.S31805. 2016
- Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget. 4:2067-2079. 2013
- A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Investigational New Drugs. 31:1244-1250. 2013
-
Phase II study of
TAS ‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Medicine. 2:351-359. 2013 - Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. e295-e300. 2013
- Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8:619-623. 2013
- Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 33:e295-e300. 2013
- Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology. Journal of Clinical Oncology. 30:2025-2027. 2012
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 74:481-485. 2011
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer. Cancer Discovery. 1:598-607. 2011
- Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29:1075-1082. 2011
- Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.. Oncology. 24:1223-1226. 2010
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 66:1079-1085. 2010
- Combined Modality Therapy of Esophageal Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 6:851-861. 2008
- Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?. Current Oncology Reports. 9:255-264. 2007
- Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemotherapy and Pharmacology. 59:621-629. 2007
- Thirty years later: We've only just begun. Oncology. 20:1663-+. 2006
- Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?. Journal of the National Comprehensive Cancer Network : JNCCN. 4:595-600. 2006
- The Horiike/Saijo article reviewed. Oncology. 19:55-56. 2005
- Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future. Current Oncology Reports. 7:248-254. 2005
- Small-cell lung cancer: Current therapy and novel agents - The Horiike/Saijo article reviewed. Oncology. 19:55-56. 2005
-
preprints